-
A new orally effective targeted therapy for the treatment of non-small cell lung cancer (NSCLC) has been approved by the FDA. Crizotinib is a receptor tyrosine kinase inhibitor including anaplastic lymphoma kinase (ALK).
-
Eating out has increased in the general population, and is associated with increased body mass index. Indeed, United States data suggest that more than one-third of all daily calories are provided from restaurants.
-
Participation in Weight Watchers resulted in a greater weight loss over a year than did clinical intervention in a primary care office.
-
In postmenopausal women, constipation is associated with having major risk factors for cardiovascular disease and increased cardiovascular risk.
-
Greater daily activity energy expenditure appears to reduce the incidence of cognitive impairment in a dose-response manner.
-
A brief amount of face-to-face and telephone counseling helps seniors sleep better without prescription medications. Direct counseling is superior to giving reading materials.
-
Single blood pressure (BP) measurements are not reflective of the average BP 20% of the time. A series of BPs should be averaged for medical decision making. A series of home BP recordings is more accurate than those in the office for assessing the control of BP among hypertensive patients.
-
Since two-thirds of americans are overweight or obese, most of us should probably be trying to better understand why.
-
A third oral antiplatelet inhibitor has been approved by the FDA to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). Ticagrelor is an adenosine diphosphate receptor P2Y12 inhibitor similar to clopidogrel and prasugrel. It is marketed by AstraZeneca as Brilinta.
-
The authors advocate that cardiovascular magnetic resonance imaging using specific criteria may be useful as a diagnostic tool for patients with stress cardiomyopathy at the time of acute clinical presentation.
